Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,411 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Process-based therapy Clear all
Completed No phase listed Observational

A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment

NCT02041689
View directory record Official record
Conditions
Sarcoma
Interventions
Interview, Observations, Guided Activities
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
7 Years to 11 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 27, 2026, 1:24 PM EDT
Recruiting Phase 2 Interventional

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

NCT05664126
View directory record Official record
Conditions
Cytomegalovirus, Adenovirus
Interventions
VST infusion, CliniMACS
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Terminated Not applicable Interventional Results available

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

NCT00255684
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Rochester
Other
Eligibility
Up to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00045136
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
melphalan, peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
Drug · Procedure · Radiation
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
5
States / cities
Birmingham, Alabama • Sacramento, California • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Specialty Medical Homes to Improve Outcomes for Patients With IBD and Behavioral Health Conditions

NCT03985800
View directory record Official record
Conditions
Inflammatory Bowel Disease, Behavioral Symptoms
Interventions
TEAM, TECH
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

NCT00052884
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, amifostine trihydrate, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
16
States / cities
Scottsdale, Arizona • Indianapolis, Indiana • Burnsville, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer

NCT02775695
View directory record Official record
Conditions
Resectable Pancreatic Cancer
Interventions
Doxycycline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 27, 2026, 1:24 PM EDT
Not listed Not applicable Interventional

The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

NCT03014401
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Arthroscopic debridement with stem cell transplantation, Arthroscopic debridement only
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
35 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
3
States / cities
Santa Monica, California • Stanford, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 27, 2026, 1:24 PM EDT
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia

NCT00004898
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Up to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Implementing and Sustaining a Sleep Treatment to Improve Community Mental Health Part 2: Train-the-Trainer

NCT05805657
View directory record Official record
Conditions
Sleep Disorder, Circadian Dysregulation
Interventions
Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C), Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C), Usual Care Delayed Treatment
Behavioral · Other
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Concord, California • Fairfield, California • Hanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy

NCT01505101
View directory record Official record
Conditions
Chronic Pain, Opioid Abuse, Unspecified Use
Interventions
Mindfulness-Oriented Recovery Enhancement, Conventional Support Group (SG)
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00003416
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, recombinant interferon alfa, dexamethasone, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 69 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

NCT01497184
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
HSCT, DLI
Procedure · Genetic
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Stress Interventions in STEM and Non-STEM

NCT05376306
View directory record Official record
Conditions
MBSR-STEM, PMR-STEM, MBSR-NON-STEM, PMR -NON-STEM
Interventions
Stress Reduction: MBSR, Stress Reduction : PMR
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 23 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

NCT00002552
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, sargramostim, carmustine, cyclophosphamide, cytarabine, etoposide, leucovorin calcium, methotrexate, perfosfamide, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2003
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

NCT00453206
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

NCT00046852
View directory record Official record
Conditions
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 27, 2026, 1:24 PM EDT
Recruiting Phase 1 Interventional

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

NCT04532047
View directory record Official record
Conditions
MPS I, MPS II, MPS IVA, MPS VI, Mps VII, Gaucher Disease, Type 2, Gaucher Disease, Type 3, Pompe Disease Infantile-Onset, Wolman Disease
Interventions
Aldurazyme (laronidase)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies

NCT00914849
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
AMD3100, Leukopheresis, Stem cell transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location

NCT02152696
View directory record Official record
Conditions
Persistent Pregnancy of Unknown Location, Ectopic Pregnancy
Interventions
Methotrexate, Uterine Evacuation, Expectant Management
Drug · Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 27, 2026, 1:24 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Stem Cell Transplantation for Hematological Malignancies

NCT00176839
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, AML, MDS
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

NCT01966367
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions
CD34 Stem Cell Selection Therapy
Biological
Lead sponsor
Diane George
Other
Eligibility
Up to 40 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Recruiting Phase 1 Interventional

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

NCT03909412
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 27, 2026, 1:24 PM EDT